CIK 0000939767 · Large accelerated filer
EXELIXIS, INC.
Sign in to watch- Ticker
- EXEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jan 1
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043257395
- Phone
- 6508377000
- Business address
- 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
- Former names
- EXELIXIS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-15 | Senner Christopher J. EVP and CFO | Shares withheld for taxes | −40,892 | $51.10 | $2.1M | 987,218 |
| 2026-05-15 | Haley Patrick J. EVP, Commercial | Shares withheld for taxes | −33,265 | $51.10 | $1.7M | 389,748 |
| 2026-05-15 | Hefti Brenda SVP and General Counsel | Shares withheld for taxes 10b5-1 | −6,411 | $51.10 | $328K | 113,387 |
| 2026-05-15 | Aftab Dana EVP, Research and Development | Shares withheld for taxes | −30,578 | $51.10 | $1.6M | 638,192 |
| 2026-05-07 | Beckerle Mary C Director | Option exercise | +3,856 | $23.24 | $90K | 25,236 |
| 2026-05-07 | Beckerle Mary C Director | Sale | −7,712 | $48.45 | $374K | 17,524 |
| 2026-05-07 | Beckerle Mary C Director | Option exercise · Option (right to buy) | −3,856 | 12,854 | ||
| 2026-05-07 | Freire Maria C Director | Option exercise | +20,634 | $19.77 | $408K | 121,453 |
| 2026-05-07 | Freire Maria C Director | Sale | −20,634 | $46.00 | $949K | 100,819 |
| 2026-05-07 | Freire Maria C Director | Option exercise · Option (right to buy) | −20,634 | 0 | ||
| 2026-05-07 | POSTE GEORGE Director | Sale | −60,000 | $45.71 | $2.7M | 118,832 |
| 2026-05-06 | MORRISSEY MICHAEL President and CEO | Gift | −109,676 | 1,880,280 | ||
| 2026-02-26 | Aftab Dana EVP, Research and Development | Grant or award | +52,018 | 668,124 | ||
| 2026-02-26 | Senner Christopher J. EVP and CFO | Grant or award | +52,018 | 1,028,110 | ||
| 2026-02-26 | Hefti Brenda SVP and General Counsel | Grant or award | +23,119 | 119,631 | ||
| 2026-02-26 | Haley Patrick J. EVP, Commercial | Grant or award | +40,459 | 422,367 | ||
| 2026-02-26 | MORRISSEY MICHAEL President and CEO | Grant or award | +160,437 | 1,614,552 | ||
| 2026-02-24 | MORRISSEY MICHAEL President and CEO | Gift | −100,278 | 1,989,956 | ||
| 2026-02-24 | Aftab Dana EVP, Research and Development | Sale | −47,918 | $44.50 | $2.1M | 616,106 |
| 2026-02-19 | Aftab Dana EVP, Research and Development | Sale | −29,873 | $44.35 | $1.3M | 664,024 |
Page 2 of 10 · 192 trades